Search | Clinical Trials Finder

Conditions: ST Elevation Myocardial Infarction
Interventions: MGuard Prime, (BMS/DES); Device
Lead sponsor: InspireMD; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 20
States / cities: New Haven, Connecticut • Tampa, Florida • Elk Grove Village, Illinois + 17 more

Conditions: Alzheimer&Amp;#39;s Disease-related Dementia, Alzheimer Disease, rTMS Stimulation
Interventions: Brain Stimulation; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 65 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-1 Infection
Interventions: JS7 plasmid DNA and MVA62B vaccine; Biological
Lead sponsor: GeoVax, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia

Conditions: Lupus Erythematosus, Systemic
Interventions: fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years to 40 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions: Percutaneous Coronary Intervention, CABG; Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Neisseria Meningitidis
Interventions: Trumenba, PENBRAYA; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Dengue
Interventions: TDENV-PIV, TDENV-F17, Placebo; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 39 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Youth Violence, Crime, Educational Achievement
Interventions: BAM, Match; Behavioral · Other
Lead sponsor: University of Chicago; Other
Eligibility: Male only
Enrollment: 5,344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections, HIV Seronegativity
Interventions: gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205); Biological
Lead sponsor: Walter Reed Army Institute of Research (WRAIR); Federal
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Stroke
Interventions: active rTMS, sham rTMS, conventional stroke therapy; Device · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Untreated Adult Acute Myeloid Leukemia, Myeloproliferative Neoplasm With 10% Blasts or Higher
Interventions: filgrastim, clofarabine, cytarabine; Biological · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 3
States / cities: Duarte, California • Stanford, California • Seattle, Washington

Conditions: Bloodloss, Surgical Procedures, Operative
Interventions: Ecallantide, Cyklokapron(R); Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Uncontrolled Hypertension, BMI, Stress, Medication Adherence
Interventions: Prime Time Sister Circle; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 359 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza, Human
Interventions: Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005, VRC-AViDNA036-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Meningitis, Meningococcal
Interventions: MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 48
States / cities: Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more

Conditions: Nipah Virus Infection
Interventions: PHV02, Lactated Ringer's; Biological
Lead sponsor: Public Health Vaccines LLC; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Anaheim, California • Hollywood, Florida • Salt Lake City, Utah

Conditions: Dysphoria
Interventions: Guided Meditation VR for Wellness, Accelerated Transcranial Magnetic Stimulation: MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP), Accelerated Transcranial Magnetic Stimulation: MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP); Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Ovarian Cancer
Interventions: Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure; Drug · Biological · Procedure
Lead sponsor: Kalinski, Pawel, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alcohol Drinking, Alcohol Use Disorder
Interventions: Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate", Isocaloric dextrose placebo, Alcohol drinks; Dietary Supplement · Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumor, Colorectal Cancer
Interventions: Magrolimab, Cetuximab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Detroit, Michigan + 5 more

Conditions: Resilience, Aging
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 60 Years and older
Enrollment: 297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Durham, North Carolina

Conditions: Blood Pressure, Hypertension
Interventions: Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Melanoma, Lymph Node Cancer
Interventions: CMP-001, Nivolumab; Drug · Biological
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Patient Compliance
Interventions: Games, Videos; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 35 Years to 64 Years
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Urbana, Illinois

Search by objective public record fields.

MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction

Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

EXCEL Clinical Trial

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Improving Life Chances of Disadvantaged Youth: Testing Best-Practice Academic vs. Non-Academic Supports

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

Repetitive Transcranial Magnetic Stimulation Use in Acute Stroke

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

PTSC: Improving Hypertension Control Among Poor Midlife African American Women

Vaccine for Prevention of Bird Flu

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

Neuromodulation for Dysphoria

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

Ketone Ester Intervention in Alcohol Use Disorder

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Physical Resilience: Indicators and Mechanisms in the Elderly (PRIME) Collaborative Phase 2

Reversing Glucose and Lipid-mediated Vascular Dysfunction

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease

Cognitive Regulation Training and Exercise Trial